VICTORIA, British Columbia, (Uptick Newswire – Feb. 22, 2018) — Emerald Health Therapeutics, Inc. (TSX-V:EMH) (OTCQX:EMHTF) (“Emerald”) has achieved the #1 ranking in the 2018 TSX Venture 50™ for the clean technology & life science sector and is recognized as a top performing company for the second consecutive year. The TSX Venture 50™ is the TSX Venture Exchange’s annual ranking of Canada’s top 50 emerging publicly traded companies.
“Emerald, like all the companies in the TSX Venture 50™ and in the rapidly growing cannabis sector, aspires to build a growing and differentiated business that will provide notable value to shareholders. In achieving #1 status in our sector in 2018, I extend a big thank you to our entire team for their effort and our shareholders for their support,” said Chris Wagner, CEO of Emerald. “We are executing very well on our major production expansion projects, are well-financed, and are advancing unique product innovation and marketing initiatives. We believe these factors strongly position Emerald for the anticipated legal adult-use cannabis market in Canada and for emerging international opportunities.”
Winner selections are based on a formula with equal weighting given to share price appreciation, market capitalization growth, and trading volume for the year ending December 31, 2017. The TSX Venture 50™ acknowledges the top 10 performing companies listed on the TSX Venture Exchange in five industry sectors: mining, oil & gas, clean technology & life sciences, diversified industries, and technology.
The TSXV created a video profile on Emerald and other 2018 TSX Venture 50™ winners, available at www.tsx.com/venture50.
Earlier this month Emerald announced that it had been upgraded to Tier 1 on the the TSX Venture Exchange. This status was based on standards regarding historical financial performance, stage of development, and financial resources. Tier 1 is the highest tier of the TSX-V and is reserved for more advanced issuers with greater financial resources.
Emerald Health Therapeutics, Inc.
Emerald Health Therapeutics, Inc. (TSX-V:EMH) (OTCQX:EMHTF) operates through Emerald Health Botanicals Inc. (“Botanicals”), a wholly owned subsidiary and Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations. Through Botanicals, Emerald is authorized to produce and sell dried medical cannabis flower and medical cannabis oil. It currently operates an indoor facility in Victoria, BC, and is building a 500,000 s.f. greenhouse on 32 acres in Metro Vancouver, with expansion potential to 1 million s.f. to serve the anticipated legal Canadian adult-use cannabis market starting in 2018. Emerald also owns 50% of Pure Sunfarms Inc., a partnership with Village Farms International Inc. that is converting an existing 1.1 million s.f. greenhouse in Delta, BC from growing tomatoes to growing cannabis. Emerald’s team is highly experienced in life sciences, product development and large-scale agribusiness. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.
Please visit www.emeraldhealth.ca for more information or contact:
Robert Hill, CFO
(800) 757 3536 Ext. #722
Cautionary Statements Regarding Forward Looking Information
Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”.
We caution you that such “forward-looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward-looking statements include, but are not limited to exercise of the Investor’s existing warrants; the development, expansion and conversion of greenhouse facilities; and the starting of adult-use cannabis market in 2018.
Emerald Health Therapeutics Inc. does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, the ability of the Company to negotiate and complete future funding transactions; variations in market conditions; and other risk factors described in the Prospectus and the Company’s other filings with the applicable Canadian securities regulators, which may be viewed at www.sedar.com. Actual results may differ materially from those expressed or implied by such forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.